
This Summer Stone Fruit Is Surprisingly Good For the Gut, Skin, and Brain
Apricots are high in fiber
One of the great advantages of apricots? 'They are rich in both soluble and insoluble fiber, so they are good for intestinal transit,' says Digón. 'In addition, they serve as food for our microbiota.'
Nutritionist Laura Parada agrees that apricots improve digestion and intestinal motility, and adds that this can have the added benefit of reducing a certain rather unpleasant condition: 'Especially in their dried form, apricots can help relieve constipation thanks to their high fiber content,' she says.
Foods rich in fiber offer a potential beauty benefit, too—especially in terms of reducing stomach bloating, which is often exacerbated in the summer thanks to heat-induced fluid retention. (Just be sure not to eat too much fiber as an excess can actually cause abdominal bloating.)
Apricots ease fluid retention
It's not just the fiber that helps eliminate bloating, either. 'Apricots also provide potassium, which has a diuretic effect and improves fluid retention,' Parada points out, noting that the natural acids present—such as malic and citric acid—can help improve digestion, intestinal health, and nutrient absorption, too. 'Although it should be noted that with ripening, the amount of these acids decreases,' she says.
Apricots are low in sugar
Digón says apricots usually contain around 20 calories per whole fruit, so eating three apricots would only count for one serving of fruit. 'Compared to other fruits, their calorie count is quite low thanks to their high amount of water and modest amount of carbohydrates,' Digón explains.
In addition, apricots are low in fructose, which means they are often recommended as a way to alleviate intestinal inflammation problems—including a bloated belly.
Apricots are good for the brain
As mentioned, apricots are beneficial for gut microbiota—which, in turn, is good for the brain. 'When we consume foods rich in fiber, our intestinal microbiota is supported in a fermentation process responsible for the release of short-chain fatty acids,' Irache Alonso, pharmacist and founder of Well-feeling Club, explains. 'Those short-chain fatty acids contribute to the reduction of neuroinflammation and favor both emotional balance and the prevention of neurodegenerative disorders.'
Apricots are high in beta-carotene
Apricots are rich in beta-carotene, which is transformed into vitamin A in our body, which then contributes to healthy skin. Thus, apricots are often recommended by dermatologists and skin experts. For example, Dr. Mar Mira of Clínica Mira + Cueto says she always includes them in her antioxidant-rich food plans. 'Apricots are another main food source of pro-vitamin A, which is essential for the skin,' she explains. Dr. María José Crispín of Clínica Menorca also refers to their high beta-carotene content, noting that the natural pigments and antioxidants support melanin production making apricots helpful for preparing the skin for sun exposure. Looks like apricots really are the quintessential summer fruit.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Is Novo Nordisk Stock a Buy, Sell, or Hold Before Q2 Earnings?
Danish pharmaceutical giant Novo Nordisk A/S (NVO) is facing serious headwinds. After enjoying a strong run fueled by demand for its obesity treatments, the obesity drug pioneer is now under pressure from rising competition, particularly from Eli Lilly's (LLY) weight-loss drugs, as well as trial setbacks for its next-generation therapies. In fact, things took a sharp turn on July 29, when the company cut its full-year sales growth guidance for the second time in just three months and named a new CEO. The market response was swift and brutal, with NVO shares plunging over 21% in a single day. Now, with second-quarter earnings just around the corner on Aug. 6, does Novo Nordisk's recent plunge present a golden buying opportunity, or is it a clear signal to keep your distance? More News from Barchart Dear Nvidia Stock Fans, Mark Your Calendars for August 27 Options Traders Expected Palantir Stock's Tamest Earnings Reaction in a Year. Did They Get It Right? Tesla Gains on Elon Musk's New Pay Package. Is TSLA Stock a Buy? Our exclusive Barchart Brief newsletter is your FREE midday guide to what's moving stocks, sectors, and investor sentiment - delivered right when you need the info most. Subscribe today! About Novo Nordisk Stock Best known for its blockbuster weight-loss drugs Ozempic and Wegovy, Novo Nordisk is a global healthcare leader with a long-standing focus on chronic disease. Founded in 1923 and headquartered in Denmark, the company has built a strong foundation in diabetes care while expanding its reach into obesity and other severe health conditions. The company commands a market capitalization of about $217.9 billion. While Novo Nordisk has been a trailblazer in the obesity drug market, its stock has hit a rough patch. Softer demand for its blockbuster drugs, combined with intensifying competition in the weight-loss space, has taken a toll on investor sentiment. The stock has tumbled a staggering 66% from its 52-week high of $139.74 reached in August 2024, and it's currently down 44.7% year-to-date (YTD). In stark contrast, the broader S&P 500 Index ($SPX) has managed to notch a gain of approximately 7.1% over the same period, while its rival Eli Lilly has seen only a marginal drop so far this year, highlighting just how far Novo has fallen out of favor with the market. Given its underwhelming price action, Novo Nordisk stock is starting to look like a value play. Currently trading at just 12.5 times forward earnings, it's priced well below the sector median of 16.87x, and dramatically lower than its own five-year average of 30.92x. Novo Nordisk's Q1 Earnings Snapshot In early May, Novo Nordisk posted a solid first-quarter earnings report for fiscal 2025, but the shine was dulled by a cautious outlook. Total revenue climbed 19% year-over-year (YOY) to 78.1 billion Danish kroner, powered by a massive 85% surge in Wegovy sales, which hit 17.4 billion Danish kroner. Ozempic also continued to perform, with sales rising 18% to 32.7 billion Danish kroner. Profits also impressed, with net profit climbing 14% to 29 billion Danish kroner, while operating profit increased 22% to 38.8 billion Danish kroner. But despite these promising numbers, Novo trimmed its full-year sales growth and operating profit growth guidance, citing 'lower-than-planned penetration of branded GLP-1 treatments in the US.' The company pointed to the growing presence of U.S. compounding pharmacies, which have been legally producing copycat versions of Wegovy and Ozempic under an FDA-approved exemption for addressing drug shortages. That growing parallel market has begun to chip away at Novo's momentum. On a more promising note, the company completed its REDEFINE 2 trial during the quarter, with its next-generation drug CagriSema delivering an impressive 15.7% weight loss in patients with obesity or overweight conditions and type 2 diabetes. Novo plans to file for its first regulatory approval in early 2026, potentially marking the next significant chapter in its obesity pipeline. Novo Nordisk Slashes Guidance Again and Names New CEO On July 29, Novo Nordisk held a conference call that left investors rattled, as it unveiled major leadership changes and another sharp downgrade to its 2025 financial outlook. The company slashed its full-year sales growth guidance to 8%-14%, down from the previously expected 13%-21%. Operating profit growth was also revised lower, now projected at 10%-16% compared to May's forecast of 16%-24%. The revised outlook sent a strong signal that Novo is bracing for a more challenging year ahead. A big part of the pressure comes from its obesity blockbuster, Wegovy. In its update, Novo pointed to several headwinds weighing on U.S. sales, including the continued rise of compounded GLP-1 knockoffs, slower-than-expected market expansion, and increasing competition. These challenges have clouded the outlook for one of Novo's key growth drivers, sparking concerns about whether the company can maintain its dominance in the rapidly growing weight-loss market. Adding to the uncertainty, Novo also announced a leadership shake-up. Maziar Mike Doustdar, the current EVP of international operations, will take over as CEO on Aug. 7, succeeding Lars Fruergaard Jørgensen, whose surprise resignation was announced in May. The transition comes at a pivotal moment, with the company under pressure to protect market share and reignite growth amid shifting dynamics in the obesity drug landscape. What Do Analysts Think About Novo Nordisk Stock? Despite all the swirling uncertainty, there's still a hint of optimism in the air. With Novo Nordisk set to unveil its Q2 earnings on Aug. 6 and a new CEO stepping in shortly after, Wall Street hasn't lost faith, with analysts leaning cautiously bullish, giving the stock a consensus rating of 'Moderate Buy' overall. Of the 19 analysts offering recommendations, seven advise a 'Strong Buy,' nine suggest a 'Hold,' one advocates a 'Moderate Sell,' and the remaining two maintain a 'Strong Sell.' NVO's average analyst price target of $71.75 suggests 47% potential upside from current levels. However, the Street-high target of $112 implies that shares can rally as much as 129.5% from current price levels. On the date of publication, Anushka Mukherji did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
Yahoo
2 hours ago
- Yahoo
Crackdown on cosmetic surgery ‘cowboys' over botched Brazilian butt lifts and Botox
Ministers want to clamp down on 'cowboy' cosmetic procedures including Botox and Brazilian butt lifts after a string of horror incidents which left customers dead or with catastrophic damage. Officials said the industry had been blighted by 'dodgy practitioners and procedures', with some patients 'maimed' during botched treatments. It follows the case of mother-of-five, Alice Webb, who is thought to be the first person to have died following a non-surgical liquid Brazilian butt lift (BBL) procedure at a UK clinic. The Department of Health and Social Care (DHSC) has proposed new restrictions on who can access and provide treatments in a bid to protect people from 'rogue operators' with no medical training who often provide 'invasive' procedures in homes, hotels and pop-up clinics. The move should also reduce the cost imposed upon the NHS to fix botched procedures, DHSC added. Tim Mitchell, president of the Royal College of Surgeons of England, hailed the proposals as an 'important first step forward for patient safety.' Health minister Karin Smyth said: 'The cosmetics industry has been plagued by a Wild West of dodgy practitioners and procedures. 'There are countless horror stories of cosmetic cowboys causing serious, catastrophic damage.' She said the government would take action too 'root out cowboys' and support 'honest and competent practitioners.' 'This isn't about stopping anyone from getting treatments – it's about preventing rogue operators from exploiting people at the expense of their safety and keeping people safe,' Ms Smyth added. 'We're giving them peace of mind and reducing the cost to the NHS of fixing botched procedures.' The government's proposals include: Only allowing healthy workers who are 'suitably qualified' to be able to deliver high-risk procedures such as (BBLs) Ensuring providers are regulated by the health regulator, the Care Quality Commission. Slapping sanctions and finanial penalties on those who break rules on high-risk procedures Ensuring clinics offering Botox and fillers are licensed Introducing age restrictions to prevent children from trying to follow 'dangerous beauty trends on social media' The timeline for the introduction and completion of these measures was not stated. But the DHSC said it will launch a consultation next year seeking views on the range of procedures which should be covered in the new restrictions. Last month, the Chartered Trading Standards Institute warned that fat injections, BBLs, Botox and fillers are being offered by untrained people in places such as public toilets. Before the proposed regulations come into force, the government has urged people seeking cosmetic procedures to ask for the provider's qualifications and insurance, and to be wary of 'suspiciously cheap' offers. Health officials launched an investigation after a number of people had reactions to Botox injections earlier this year. Professor David Sines CBE, the chair and registrar of Joint Council for Cosmetic Practitioners (JCCP), said the move will 'protect the public from untrained and inexperienced operators and it will save the NHS a considerable amount of time and money putting right the harm done through botched procedures.' The statement added the need for the new measures had become increasingly clear in recent years with the 'explosion of high street outlets offering high-risk procedures delivered by people with limited clinical knowledge and training.' He warned this has led to long-term health complications and, in some cases, has led to patient deaths. Mr Mitchell suggested the government must go further on liquid Brazilian Butt Lifts, which the RCS said the procedure should only be performed by a Cosmetic Surgery Board-certified surgeon. The surgeon warned that the procedure needs medical oversight to prevent serious complications and said that while the government's plans will improve the regulation of non-surgical interventions, it must also urgently improve the regulation of surgical procedures. Millie Kendall, chief executive of the British Beauty Council, said: 'Any measures that increase protection for the general public and professionalise the industry will help instil confidence as well as helping to prevent the normalisation of horror stories that have become synonymous with our sector.'


Fox News
2 hours ago
- Fox News
Mosquito-borne virus spreading through China causes high fever, joint pain
A mosquito-borne virus has led to a widespread outbreak in China, sparking concerns about global impact. The U.S. Centers for Disease Control and Prevention (CDC) has issued a Level 2 alert for an outbreak of chikungunya virus in the Guangdong Province, where health officials have reported more than 7,000 cases as of Wednesday, per the AP. The virus spreads when a mosquito feeds on an infected person and then bites another person. There are efforts underway to control the mosquitoes spreading the virus, including the use of nets, insecticide and drones, the report stated. Chikungunya cases have also been spreading throughout Europe, according to the European Centre for Disease Prevention and Control (ECDC). Since the beginning of 2025, approximately 240,000 CHIKVD cases and 90 deaths have been reported in 16 countries and territories, including the Americas, Africa, Asia and Europe, the health agency reported in July. There have been no confirmed locally acquired cases in the U.S. since 2019, according to CDC data. Common symptoms of chikungunya include high fever and joint pain, according to Dr. Marc Siegel, Fox News senior medical analyst. They usually begin between three and seven days after being bitten by an infected mosquito. Some people may also experience headache, joint swelling, rash and muscle pain, the CDC stated. In most cases, symptoms abate within a week, but some may suffer from severe joint pain for months or years after infection. "Occasionally, neurological complications arise, including encephalitis (swelling of the brain)." "Occasionally, neurological complications arise, including encephalitis (swelling of the brain)," Siegel cautioned. People at highest risk of severe illness include adults 65 and older, newborns and people with comorbidities, such as heart disease or diabetes, the CDC said. Chikungunya is rarely fatal. The chikungunya virus is not transmitted among humans, and cannot be spread through physical contact, coughing or sneezing, the CDC stated. While there have been cases of chikungunya in Southeast Asia, the high volume in Southern China is new, Siegel noted. "China's strategy for containment is also very restrictive and draconian, and won't likely work," he told Fox News Digital. The country has shared plans to use drones to seek out standing water where mosquitoes breed, as well as spraying parks, public places and even people with insect repellents, the doctor said. "Officials are going door to door dressed in red vests and fining or arresting anyone who has still water," Siegel said, citing a New York Times report. "They are also quarantining sick people in the hospital for a week under mosquito netting." Another tactic is using elephant mosquitoes, which produce larvae that eat the Aedes mosquitoes that spread the virus, Siegel added. "None of this is likely to work, as people live too close together and these mosquitoes breed easily," he said. There are not currently any specific medications to treat chikungunya virus. The best way to keep the virus at bay is to prevent mosquito bites, according to experts. Recommended prevention strategies include using EPA-registered insect repellent, wearing long-sleeved shirts and pants, keeping screens on windows, using mosquito netting if sleeping outside, and treating clothing and gear with 0.5% permethrin (a synthetic chemical used primarily as an insecticide). For more Health articles, visit Two vaccines are available in the U.S. — a live-attenuated vaccine (IXCHIQ) and a virus-like particle vaccine (VIMKUNYA), which may be recommended for higher-risk travelers who plan to visit places where the virus is prevalent, the CDC stated. Travelers should speak with a healthcare provider to determine whether they are candidates for the vaccine.